Pulmatrix, Inc.
The research record contains a warning or limitation that requires review before a complete Wall Street Score can be published. Available company and financial research remain accessible.
PULM · Price history
Price at last available close
$1.49
−$0.10 (-6.29%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Pulmatrix, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology.
How they make money
Pulmatrix is a clinical-stage biopharmaceutical company that focuses on the development of inhaled therapeutic products. Its business model relies on the research and development of proprietary drug candidates using its iSPERSE technology, with the intent to monetize these assets through licensing agreements, strategic partnerships, or future commercialization of its pipeline.
Products & services
The company develops inhaled therapeutic products for respiratory and CNS diseases using its proprietary iSPERSE dry powder delivery platform.
Brands & revenue mix
Proprietary engineered dry powder delivery platform.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials.Source
Business relationships & partnerships
- MannKind Corporation — In July 2024, MannKind acquired an exclusive license to the Pulmatrix iSPERSE formulation.Source
Strengths
- Proprietary iSPERSE dry powder delivery platformSource
Company-specific research
Questions worth answering for PULM
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can PULM fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PULM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PULM to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PULM's current valuation?
- •What does the current missing revenue history warning mean for the reliability or interpretation of PULM's score?
Essential Investment Snapshot
Market Cap
$5.4M
P/E Ratio
-1.2
EPS
$-1.10
52-Week High
$5.24
52-Week Low
$1.16
Beta
1.93
Shares Outstanding
3.7M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$0.70
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PULM
Detected from reported data — verify before acting.M&A headline · Aug 13, 2026
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
PRNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on PULM.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary iSPERSE dry powder delivery platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and dependence on additional financing.
- −Reliance on third-party manufacturers and clinical research organizations.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$1.49
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $7.8M | $7.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $38K | $38K | $7.2M | $15.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$38K | -$38K | $640K | -$8.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $16K | $38K | $7.2M | $15.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $4.1M | $5.1M | $7.8M | $6.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $4.1M | $5.1M | $10.4M | $6.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$4.0M | -$5.2M | -$6.7M | -$12.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$4.1M | -$5.2M | -$9.8M | -$14.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$4.0M | -$5.2M | -$9.6M | -$14.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$4.0M | -$5.2M | -$9.6M | -$14.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.10 | $-1.41 | $-2.62 | $-3.87 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 3.65M | 3.65M | 3.65M | 3.65M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 3.65M | 3.65M | 3.65M | 3.65M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.29
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
-62.8%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Cash position declined
Potential Score Impact
Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 31.0%. Cash declined 62.8%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Rumor Mill · PULM
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial